Regrelor

Star0

DB05553InvestigationalSmall molecule

Investigated for use/treatment in cardiac surgery, coronary artery disease, thrombosis, and transfusion.

Mechanism: Pharmacologically active on P2Y purinoceptor 12
Curator reviewed
Primary indication: Investigated for use/treatment in cardiac surgery, coronary artery disease, thrombosis, and transfusion.Curator reviewed
Formula / weight: C₂₂H₂₅N₆O₈P · 532.45 g/mol (avg)

Resolves to

Compound

UNIIQ6C8TY6SW1CAS787548-03-2ChEMBLCHEMBL1162175

Clinical / RWD

RxNorm1313722

Structure

InChIKeyNXHAXEBZOXCDKD-XIXRRVGJSA-NSMILES[H][C@]12O[C@@H](O[C@@]1([H])[C@@H](O[C@@H]2COP(O)(O)=O)N1C=NC2=C1N=CN=C2NC(=O)NCC)\C=C\C1=CC=CC=C1

Targets

Q9H244P2RY12

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Regrelor, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account